458 related articles for article (PubMed ID: 25999184)
1. Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid Arthritis.
Baser O; Ganguli A; Roy S; Xie L; Cifaldi M
Clin Ther; 2015 Jul; 37(7):1454-65. PubMed ID: 25999184
[TBL] [Abstract][Full Text] [Related]
2. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
[TBL] [Abstract][Full Text] [Related]
3. The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients.
Shahabi A; Shafrin J; Zhao L; Green S; Curtice T; Marshall A; Paul D
J Med Econ; 2019 Apr; 22(4):350-358. PubMed ID: 30653389
[TBL] [Abstract][Full Text] [Related]
4. Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis.
Vanderpoel J; Tkacz J; Brady BL; Ellis L
Clin Ther; 2019 Jun; 41(6):1080-1089.e5. PubMed ID: 31122662
[TBL] [Abstract][Full Text] [Related]
5. Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: A 1-year mirror-image study using a national claims database.
Chen KC; Wu CH; Tang CH; Huang KC
PLoS One; 2018; 13(7):e0200758. PubMed ID: 30020997
[TBL] [Abstract][Full Text] [Related]
6. Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis.
McBride S; Sarsour K; White LA; Nelson DR; Chawla AJ; Johnston JA
J Rheumatol; 2011 Oct; 38(10):2141-9. PubMed ID: 21844154
[TBL] [Abstract][Full Text] [Related]
7. Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting.
Meissner B; Trivedi D; You M; Rosenblatt L
J Med Econ; 2014 Apr; 17(4):259-65. PubMed ID: 24575891
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.
Chastek B; Becker LK; Chen CI; Mahajan P; Curtis JR
J Med Econ; 2017 May; 20(5):464-473. PubMed ID: 28010149
[TBL] [Abstract][Full Text] [Related]
9. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis.
Harnett J; Wiederkehr D; Gerber R; Gruben D; Koenig A; Bourret J
J Med Econ; 2016; 19(2):91-102. PubMed ID: 26401963
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.
Cannon GW; DuVall SL; Haroldsen CL; Caplan L; Curtis JR; Michaud K; Mikuls TR; Reimold A; Collier DH; Joseph GJ; Harrison DJ; Sauer BC
Adv Ther; 2016 Aug; 33(8):1347-59. PubMed ID: 27352377
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons.
Wolf D; Skup M; Yang H; Fang AP; Kageleiry A; Chao J; Mittal M; Lebwohl M
Clin Ther; 2017 Apr; 39(4):849-862.e6. PubMed ID: 28363696
[TBL] [Abstract][Full Text] [Related]
12. Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study.
Dalén J; Luttropp K; Svedbom A; Black CM; Kachroo S
Adv Ther; 2020 Sep; 37(9):3746-3760. PubMed ID: 32647910
[TBL] [Abstract][Full Text] [Related]
13. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
14. Cost of biologic treatment persistence or switching in rheumatoid arthritis.
Gu T; Mutebi A; Stolshek BS; Tan H
Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP338-SP345. PubMed ID: 30020745
[TBL] [Abstract][Full Text] [Related]
15. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
16. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
[TBL] [Abstract][Full Text] [Related]
17. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A
Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056
[TBL] [Abstract][Full Text] [Related]
18. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
19. Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic review.
Sullivan SD; Alfonso-Cristancho R; Carlson J; Mallya U; Ringold S
J Med Econ; 2013; 16(3):391-6. PubMed ID: 23298329
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data.
Gharaibeh M; Bonafede M; McMorrow D; Hernandez EJM; Stolshek BS
J Manag Care Spec Pharm; 2020 Aug; 26(8):1039-1049. PubMed ID: 32715967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]